Focused On-demand Library for Small ribosomal subunit protein uS3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P23396

UPID:

RS3_HUMAN

Alternative names:

40S ribosomal protein S3

Alternative UPACC:

P23396; B2R7N5; J3KN86; Q498B5; Q8NI95

Background:

Small ribosomal subunit protein uS3, also known as 40S ribosomal protein S3, is integral to the small ribosomal subunit, facilitating protein synthesis within cells. It possesses endonuclease activity, contributing to DNA repair by cleaving damaged DNA. This protein binds to DNA lesions like 8-oxoG, indicative of its role in combating oxidative stress. Additionally, it interacts with various proteins to regulate DNA repair, transcription, and apoptosis, highlighting its multifunctional nature.

Therapeutic significance:

Understanding the role of Small ribosomal subunit protein uS3 could open doors to potential therapeutic strategies. Its involvement in DNA repair, apoptosis, and transcription regulation positions it as a key player in cellular health and disease prevention.